MARAVAI LIFESCIENCES HLDGS-A (MRVI)
US56600D1072 - Common Stock
We assign a fundamental rating of 3 out of 10 to MRVI. MRVI was compared to 55 industry peers in the Life Sciences Tools & Services industry. The financial health of MRVI is average, but there are quite some concerns on its profitability. MRVI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MRVI had negative earnings in the past year.
In the past year MRVI had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MRVI reported negative net income in multiple years.
In the past 5 years MRVI always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of MRVI (-9.13%) is comparable to the rest of the industry.
MRVI has a Return On Equity (-30.24%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.13% | ||
| ROE | -30.24% | ||
| ROIC | N/A |
ROA(3y)3.71%
ROA(5y)3.14%
ROE(3y)23.17%
ROE(5y)30.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MRVI's Gross Margin of 46.73% is in line compared to the rest of the industry. MRVI outperforms 54.55% of its industry peers.
In the last couple of years the Gross Margin of MRVI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.3%
GM growth 5Y-0.98%
2. Health
2.1 Basic Checks
MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRVI has been reduced compared to 1 year ago.
The number of shares outstanding for MRVI has been reduced compared to 5 years ago.
MRVI has a worse debt/assets ratio than last year.
2.2 Solvency
MRVI has an Altman-Z score of 1.60. This is a bad value and indicates that MRVI is not financially healthy and even has some risk of bankruptcy.
MRVI has a Altman-Z score (1.60) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.26 is on the high side and indicates that MRVI has dependencies on debt financing.
The Debt to Equity ratio of MRVI (1.26) is worse than 81.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.6 |
ROIC/WACCN/A
WACC11.45%
2.3 Liquidity
MRVI has a Current Ratio of 10.00. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
MRVI has a better Current ratio (10.00) than 94.55% of its industry peers.
A Quick Ratio of 9.28 indicates that MRVI has no problem at all paying its short term obligations.
MRVI has a better Quick ratio (9.28) than 92.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10 | ||
| Quick Ratio | 9.28 |
3. Growth
3.1 Past
The earnings per share for MRVI have decreased strongly by -108.11% in the last year.
The Revenue for MRVI has decreased by -67.28% in the past year. This is quite bad
Measured over the past years, MRVI shows a quite strong growth in Revenue. The Revenue has been growing by 18.47% on average per year.
EPS 1Y (TTM)-108.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-67.28%
Revenue growth 3Y0.57%
Revenue growth 5Y18.47%
Sales Q2Q%-2.49%
3.2 Future
MRVI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 66.82% yearly.
The Revenue is expected to grow by 14.08% on average over the next years. This is quite good.
EPS Next Y-254.33%
EPS Next 2Y-20.78%
EPS Next 3Y45.83%
EPS Next 5Y66.82%
Revenue Next Year-3.3%
Revenue Next 2Y1.77%
Revenue Next 3Y5.96%
Revenue Next 5Y14.08%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
MRVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
MRVI is valuated quite expensively with a Price/Forward Earnings ratio of 277.23.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MRVI is on the same level as its industry peers.
MRVI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 277.23 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MRVI is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7574.84 |
4.3 Compensation for Growth
MRVI's earnings are expected to grow with 45.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.78%
EPS Next 3Y45.83%
5. Dividend
5.1 Amount
MRVI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MARAVAI LIFESCIENCES HLDGS-A
NASDAQ:MRVI (11/22/2024, 8:00:00 PM)
After market: 5.28 +0.06 (+1.15%)5.22
+0.26 (+5.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.32B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 277.23 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.13% | ||
| ROE | -30.24% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10 | ||
| Quick Ratio | 9.28 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-108.11%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-254.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-67.28%
Revenue growth 3Y0.57%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y